Merck's Pneumococcal Vaccine Market Expansion Stalled By Ever-Changing, Crowded Field

 
• By Sarah Karlin-Smith

The CDC’s ACIP again punted a decision on whether to make a pneumococcal vaccine available to all adults 50 and older amid concerns over cost and equity tradeoffs, as well as unknowns about the length of vaccine protection. 

close up of foot kicking can down the road
The ACIP, for the second time, decided to delay its decision on broadening its adult pneumococcal vaccine recommendation. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers